Takeda, Amgen Sign Mega Japanese Deal
This article was originally published in PharmAsia News
Amgen and Takeda Pharmaceutical have signed a deal worth up to $1.18 billion that provides Takeda with Japanese rights to up to 12 new biopharmaceuticals from Amgen's pipeline. In addition, Takeda will acquire Amgen's Japanese unit and receive worldwide rights to Amgen's experimental cancer therapy motesanib diphosphate. In return, Amgen will retain Japanese co-promotion rights and receive at least 10 percent royalties on sales in Japan. Takeda will pay Amgen $200 million up front and as much as $702 million in milestones for the 12 compounds, as well as $100 million up front for motesanib diphosphate and up to $175 million in milestones. The deal comes as Takeda looks to shore up its pipeline prior to patent expiration of best-selling diabetes drug Actos, and as Amgen struggles to regain its footing in the wake of safety concerns over its anemia franchise. (Click here for more
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.